In our collected clinical samples, increased OGT expression and higher O-GlcNAcylation level were presented in CD34+ cells from MDS/AML patients who were non-responsive than those who were responsive to DAC treatment (DAC-NR vs DAC-R, Fig. 1B, C). This evidence concerns the gene OGT and myelodysplastic syndrome.